We validated the oncogene status of HLM regulators via integration with DEGs associated with various clinicopathological characteristics (TN, GS, pT, and TP53 mutation) and RFS outcomes and found 6 intersecting genes, EZH2, NSD2, KMT5C, UHRF1, ORC1, and DNMT3A, which were highly expressed in association with all advanced-stage parameters (tumor, GS > 7, pT3, HR > 1, and TP53 mutation). This evidence concerns the gene NSD2 and neoplasm.